| | Number | Age | Sex | | Disease | | Erosive |
|---|
| | of subjects | (years) | (F/total) | | duration (years) | CRP | disease |
|---|
All patients | 45 | 55 | 34/45 | | 10 | 15 | 27/42 |
| | | (23–86) | (76%) | | (0.5–30) | (0–95) | (64%) |
Patients with | | 54 | 15/19 | | 8 | 10 | 12/18 |
high anti-CII levels | 19 | (31–86) | (79%) | | (0.5–30) | (0–95) | (67%) |
Patients with low | 26 | 55 | 19/26 | | 12.5 | 20 | 15/24 |
anti-CII levels | | (23–78) | (73%) | | (2.0–30) | (0–62) | (63%) |
Healthy controls | 25 | 51 | 22/25 | | – | ND | – |
| | | (36–61) | (88%) | | | | |
| | Number of | Number of | | | Mean daily | | |
| | swollen | tender | NSAID | Steroid | prednisolone | MTX | DMARD |
| | joints | joints | therapy | therapy | dosage | therapy | therapy |
All patients | 2 | 4 | 26/42 | 13/42 | 2.0 | 13/42 | 30/42 |
| | (0–17) | (0–17) | (62%) | (31%) | | (31%) | (71%) |
Patients with | 9 | 6 | 10/18 | 4/18 | 1.1 | 5/18 | 9/18 |
high anti-CII levels | (0–17) | (0–17) | (56%) | (22%) | | (28%) | (50%) |
Patients with low | 2 | 3 | 16/24 | 9/24 | /2.7 | 8/24 | 21/24 |
anti-CII levels | (0-15) | (0–16) | (67%) | (38%) | | (33%) | (88%) |
Healthy controls | – | – | – | – | – | – | – |
- Data are given as median values and ranges for the various groups. Daily prednisolone dosages are presented as mean values in mg. Disease Modifying antirheumatic drugs (DMARDs) include sulfasalazin (0/18 high anti-CII patients treated, 6/24 low anti-CII patients treated,), cyklosporine (1/18 high anti-CII, 1/24 low anti-CII), Reumacon (a podophyllin derivative, 1/18 high anti-CII, 1/24 low anti-CII), chloroquine (0/18 high anti-CII, 2/24 low anti-CII), aurathiomalase (0/18 high anti-CII, 3/24 low anti-CII), auranofin (1/18 high anti-CII, 0/24 low anti-CII) and azatioprin (1/18 high Anti-CII, 1/24 low anti-CII). Figures for sex distribution, erosiveness and medications are given both as fraction of number positive/number Investigated, and as percentage. Data on erosive disease are based on X-ray evaluations. Patient charts were not available for three patients, one With high anti-CII levels and two with low anti-CII levels. F, female; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drug; MTX, Methotrexate; ND, not done; CII, collagen type II.
